1. AWMF S2k Leitlinie Fertilitätsprotektion (2017) – ist es dies: Fertility preservation for patients with malig nant disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No.015/082, November 2017). http://www.awmf.org/leitlinien/detail/ll/015-082.html. Zugegriffen am 28.11.2022
2. AWMF S3 Leitlinie „Diagnostik, Therapie und Nachsorge bei Keim zelltumoren des Hodens“ (2020) (043/049OL). https://www.awmf.org/uploads/tx_szleitlinien/043-049OLl_S3_Keimzelltumoren-Hoden-Diagnostik-Therapie-Nachsorge_2020-03.pdf. Zugegriffen am 28.02.2023
3. Bokemeyer C, Berger CC, Hartmann JT et al (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77:1355
4. Brydoy M, Fossa SD, Klepp O et al (2005) Paternity following treatment for testicular cancer. J Natl Cancer Inst 97:1580–1588
5. Brydoy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O, Fossa SD (2009) Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101(24):1682–1695